200 related articles for article (PubMed ID: 32070860)
41. A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
Evans KW; Yuca E; Akcakanat A; Scott SM; Arango NP; Zheng X; Chen K; Tapia C; Tarco E; Eterovic AK; Black DM; Litton JK; Yap TA; Tripathy D; Mills GB; Meric-Bernstam F
Clin Cancer Res; 2017 Nov; 23(21):6468-6477. PubMed ID: 29093017
[No Abstract] [Full Text] [Related]
42. Orthotopic and metastatic tumour models in preclinical cancer research.
Stribbling SM; Beach C; Ryan AJ
Pharmacol Ther; 2024 May; 257():108631. PubMed ID: 38467308
[TBL] [Abstract][Full Text] [Related]
43. Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse.
du Manoir S; Orsetti B; Bras-Gonçalves R; Nguyen TT; Lasorsa L; Boissière F; Massemin B; Colombo PE; Bibeau F; Jacot W; Theillet C
Mol Oncol; 2014 Mar; 8(2):431-43. PubMed ID: 24394560
[TBL] [Abstract][Full Text] [Related]
44. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
Kerbel RS; Shaked Y
Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
[TBL] [Abstract][Full Text] [Related]
45. Genomic Validation of Endometrial Cancer Patient-Derived Xenograft Models as a Preclinical Tool.
Villafranca-Magdalena B; Masferrer-Ferragutcasas C; Lopez-Gil C; Coll-de la Rubia E; Rebull M; Parra G; García Á; Reques A; Cabrera S; Colas E; Gil-Moreno A; Moiola CP
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35682944
[TBL] [Abstract][Full Text] [Related]
46. Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer.
Hao C; Wang L; Peng S; Cao M; Li H; Hu J; Huang X; Liu W; Zhang H; Wu S; Pataer A; Heymach JV; Eterovic AK; Zhang Q; Shaw KR; Chen K; Futreal A; Wang M; Hofstetter W; Mehran R; Rice D; Roth JA; Sepesi B; Swisher SG; Vaporciyan A; Walsh GL; Johnson FM; Fang B
Cancer Lett; 2015 Feb; 357(1):179-185. PubMed ID: 25444907
[TBL] [Abstract][Full Text] [Related]
47. Capturing colorectal cancer inter-tumor heterogeneity in patient-derived xenograft (PDX) models.
Prasetyanti PR; van Hooff SR; van Herwaarden T; de Vries N; Kalloe K; Rodermond H; van Leersum R; de Jong JH; Franitza M; Nürnberg P; Todaro M; Stassi G; Medema JP
Int J Cancer; 2019 Jan; 144(2):366-371. PubMed ID: 30151914
[TBL] [Abstract][Full Text] [Related]
48. Impact of immediate cryopreservation on the establishment of patient derived xenografts from head and neck cancer patients.
Abel L; Durmaz A; Hu R; Longhurst C; Baschnagel AM; Wheeler D; Scott JG; Kimple RJ
J Transl Med; 2021 Apr; 19(1):180. PubMed ID: 33910584
[TBL] [Abstract][Full Text] [Related]
49. Current Update of Patient-Derived Xenograft Model for Translational Breast Cancer Research.
Kawaguchi T; Foster BA; Young J; Takabe K
J Mammary Gland Biol Neoplasia; 2017 Jun; 22(2):131-139. PubMed ID: 28451789
[TBL] [Abstract][Full Text] [Related]
50. Patient-derived xenograft models of neuroendocrine prostate cancer.
Shi M; Wang Y; Lin D; Wang Y
Cancer Lett; 2022 Jan; 525():160-169. PubMed ID: 34767925
[TBL] [Abstract][Full Text] [Related]
51. A single nucleotide polymorphism genotyping platform for the authentication of patient derived xenografts.
El-Hoss J; Jing D; Evans K; Toscan C; Xie J; Lee H; Taylor RA; Lawrence MG; Risbridger GP; MacKenzie KL; Sutton R; Lock RB
Oncotarget; 2016 Sep; 7(37):60475-60490. PubMed ID: 27528024
[TBL] [Abstract][Full Text] [Related]
52. Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data.
Nunes M; Vrignaud P; Vacher S; Richon S; Lièvre A; Cacheux W; Weiswald LB; Massonnet G; Chateau-Joubert S; Nicolas A; Dib C; Zhang W; Watters J; Bergstrom D; Roman-Roman S; Bièche I; Dangles-Marie V
Cancer Res; 2015 Apr; 75(8):1560-6. PubMed ID: 25712343
[TBL] [Abstract][Full Text] [Related]
53. Patient-derived xenografts undergo mouse-specific tumor evolution.
Ben-David U; Ha G; Tseng YY; Greenwald NF; Oh C; Shih J; McFarland JM; Wong B; Boehm JS; Beroukhim R; Golub TR
Nat Genet; 2017 Nov; 49(11):1567-1575. PubMed ID: 28991255
[TBL] [Abstract][Full Text] [Related]
54. Comparison of classical tumour growth models for patient derived and cell-line derived xenografts using the nonlinear mixed-effects framework.
Voulgarelis D; Bulusu KC; Yates JWT
J Biol Dyn; 2022 Dec; 16(1):160-185. PubMed ID: 35404766
[TBL] [Abstract][Full Text] [Related]
55. High-sensitivity Detection of Micrometastases Generated by GFP Lentivirus-transduced Organoids Cultured from a Patient-derived Colon Tumor.
Okazawa Y; Mizukoshi K; Koyama Y; Okubo S; Komiyama H; Kojima Y; Goto M; Habu S; Hino O; Sakamoto K; Orimo A
J Vis Exp; 2018 Jun; (136):. PubMed ID: 29985333
[TBL] [Abstract][Full Text] [Related]
56. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.
Townsend EC; Murakami MA; Christodoulou A; Christie AL; Köster J; DeSouza TA; Morgan EA; Kallgren SP; Liu H; Wu SC; Plana O; Montero J; Stevenson KE; Rao P; Vadhi R; Andreeff M; Armand P; Ballen KK; Barzaghi-Rinaudo P; Cahill S; Clark RA; Cooke VG; Davids MS; DeAngelo DJ; Dorfman DM; Eaton H; Ebert BL; Etchin J; Firestone B; Fisher DC; Freedman AS; Galinsky IA; Gao H; Garcia JS; Garnache-Ottou F; Graubert TA; Gutierrez A; Halilovic E; Harris MH; Herbert ZT; Horwitz SM; Inghirami G; Intlekofer AM; Ito M; Izraeli S; Jacobsen ED; Jacobson CA; Jeay S; Jeremias I; Kelliher MA; Koch R; Konopleva M; Kopp N; Kornblau SM; Kung AL; Kupper TS; LeBoeuf NR; LaCasce AS; Lees E; Li LS; Look AT; Murakami M; Muschen M; Neuberg D; Ng SY; Odejide OO; Orkin SH; Paquette RR; Place AE; Roderick JE; Ryan JA; Sallan SE; Shoji B; Silverman LB; Soiffer RJ; Steensma DP; Stegmaier K; Stone RM; Tamburini J; Thorner AR; van Hummelen P; Wadleigh M; Wiesmann M; Weng AP; Wuerthner JU; Williams DA; Wollison BM; Lane AA; Letai A; Bertagnolli MM; Ritz J; Brown M; Long H; Aster JC; Shipp MA; Griffin JD; Weinstock DM
Cancer Cell; 2016 Apr; 29(4):574-586. PubMed ID: 27070704
[TBL] [Abstract][Full Text] [Related]
57. Patient-derived tumour xenografts as models for breast cancer drug development.
Marangoni E; Poupon MF
Curr Opin Oncol; 2014 Nov; 26(6):556-61. PubMed ID: 25188472
[TBL] [Abstract][Full Text] [Related]
58. Subrenal capsule grafting technology in human cancer modeling and translational cancer research.
Wang Y; Wang JX; Xue H; Lin D; Dong X; Gout PW; Gao X; Pang J
Differentiation; 2016; 91(4-5):15-9. PubMed ID: 26547391
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
Rosato RR; Dávila-González D; Choi DS; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
Breast Cancer Res; 2018 Sep; 20(1):108. PubMed ID: 30185216
[TBL] [Abstract][Full Text] [Related]
60. Patient-derived xenografts as in vivo models for research in urological malignancies.
Inoue T; Terada N; Kobayashi T; Ogawa O
Nat Rev Urol; 2017 May; 14(5):267-283. PubMed ID: 28248952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
